TICKERNERD
Menu
CLGNCLGNHealthcare · Biotechnology

CLGN Stock Forecast: CollPlant Biotechnologies Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.97
+14.74% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$6.4M
Ticker Nerd rank
26 / 100
Median analyst target
—
Analysts covering
1
Revenue$73K
Operating income−$3.1M
Net income−$3.1M
Free cash flow−$3.1M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.2%
1M
+10.9%
YTD
−71.6%
1Y
−82.7%
From 52W high
−84.1%
From 52W low
+45.4%
$3
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CollPlant Biotechnologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Accruals
76
Issuance
69
Volatility
45
Growth
43
Revisions
25
Momentum
18
Value
8
Quality
7

Size (93): Smaller than most of the companies we track.

Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26CLGN

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Feb 2026D. Boral CapitalDowngradeHold—
28 Nov 2025D. Boral CapitalMaintainsBuy—
20 Oct 2025D. Boral CapitalMaintainsBuy—
16 Sept 2025D. Boral CapitalMaintainsBuy—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—
30 May 2025D. Boral CapitalMaintainsBuy—
28 May 2025D. Boral CapitalMaintainsBuy—
27 Mar 2025D. Boral CapitalMaintainsBuy—
12 Feb 2025D. Boral CapitalMaintainsBuy—
4 Feb 2025D. Boral CapitalMaintainsBuy—
29 Nov 2024HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024D. Boral CapitalMaintainsBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesBuy—
20 Aug 2024EF HuttonMaintainsBuy—
5 Aug 2024EF HuttonInitiatesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
5 Apr 2024HC Wainwright & Co.ReiteratesBuy—
30 Nov 2023HC Wainwright & Co.ReiteratesBuy—
25 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, CollPlant Biotechnologies Ltd. returned −82.7% against +16.2% for the S&P 500, dividends included.

CLGN vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CLGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CollPlant Biotechnologies Ltd. (CLGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
20.2×

Cheaper than 9% of US stocks

Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
−0.4×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−39.7%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
−332.9%

Higher than 1% of US stocks

Operating margin
−2438.0%

Higher than 4% of US stocks

Net margin
64.8%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−162.0%

Higher than 9% of US stocks

Return on assets
−62.9%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CollPlant Biotechnologies Ltd. (CLGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CollPlant Biotechnologies Ltd. has a market value of $6.4M and an enterprise value of $4.8M.

  • Revenue in the twelve months to 31 Mar 2026: $389K. The latest quarter shrank 39.7% year on year.

  • Net income over the same four quarters: −$13.1M, a −3376.3% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$11.3M, after $25K of capital spending.

  • Shares outstanding: 14.4M.

  • Trailing P/E: −3.5×; forward P/E: −8.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CollPlant Biotechnologies Ltd. employs 39 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CLGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLGNCollPlant Biotechnologies Ltd.$6.4M
26
SNGXSoligenix, Inc.$7.5M
27
CURXCuranex Pharmaceuticals, Inc.$7.5M
6
LGVNLongeveron, Inc.$7.6M
28
SKYESkye Bioscience, Inc.$7.4M
36
FBLGFibroBiologics, Inc.$7.4M
42
TRAWTraws Pharma, Inc.$7.3M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CollPlant Biotechnologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLGN news & analysis

LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations

PRNewsWire · 6 Oct 2026positive

CollPlant announced that its subsidiary, LightSolver, filed a U.S. provisional patent application for an invention expanding the capabilities of its all-optical, laser-based computing platform to advanced scientific and engineering simulations.

Why it matters — The filing adds to LightSolver’s intellectual property portfolio and reflects CollPlant’s photonic computing strategy.

COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

PRNewsWire · 30 Sept 2026positive

CollPlant Biotechnologies announced its 2026 second quarter financial results and provided a corporate update. The company highlighted a strategic expansion into photonic computing through its acquisition of LightSolver, which diversifies its technology portfolio alongside continued innovations in regenerative medicine.

Why it matters — CLGN watchers would care because the LightSolver acquisition marks a significant strategic diversification for the company beyond its core regenerative medicine business.

LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

PRNewsWire · 24 Sept 2026positive

CollPlant announced the publication of peer-reviewed joint research conducted by its subsidiary LightSolver with HLRS. The study, published by ACM, demonstrated that LightSolver's LPU architecture projected significantly lower time-to-solution compared to state-of-the-art algorithms running on a GPU for fundamental HPC workloads.

Why it matters — The peer-reviewed validation of LightSolver's photonic computing performance highlights progress in one of CollPlant's key subsidiaries.

CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

PRNewsWire · 22 Sept 2026positive

Nasdaq confirmed that CollPlant Biotechnologies has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), officially closing the compliance matter. This follows the recent completion of the LightSolver acquisition, which marks CollPlant's expansion into high-performance computing and photonics.

Why it matters — CLGN watchers would care because the company has resolved a Nasdaq listing compliance issue, removing a potential risk to its continued listing status.

CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript

Seeking Alpha · 17 Sept 2026neutral

CollPlant Biotechnologies discussed its acquisition of Lightsolver and strategic entry into high-performance photonic computing. The discussion appears in a Seeking Alpha transcript covering the company's move into this new computing space.

Why it matters — The acquisition signals CollPlant's diversification into photonic computing, a significant strategic shift beyond its core biotechnology focus that CLGN watchers would want to track.

FAQ

Frequently asked questions about CLGN stock

Is CLGN stock a buy right now?

Of the 1 analysts covering CollPlant Biotechnologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CollPlant Biotechnologies Ltd. 26 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLGN?

As at 8 Oct 2026, CollPlant Biotechnologies Ltd. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the CLGN stock forecast for 2030?

No analyst covering CollPlant Biotechnologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLGN are extrapolating price history, which says nothing about the business.

How has CLGN stock performed over the past year?

CollPlant Biotechnologies Ltd. returned -82.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CollPlant Biotechnologies Ltd. do?

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology.

What is the latest news on CLGN?

The most recent item we track (PRNewsWire, 6 Oct 2026): "LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations". CollPlant announced that its subsidiary, LightSolver, filed a U.S. provisional patent application for an invention expanding the capabilities of its all-optical, laser-based computing platform to advanced scientific and engineering simulations.

Company

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology. The company’s current portfolio centers on 3D bioprinting for tissues and organs, tissue repair, advanced wound care, and medical aesthetics. Its offerings include bioinks and collagen-based materials designed for regenerative applications, along with products used in soft tissue repair and wound management. CollPlant Biotechnologies also works with partners and collaborators in the broader medical device and biotech ecosystem, supporting applications in orthobiologics, surgical repair, and aesthetic medicine. Headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. plays a niche role in the market by combining plant-based biotechnology with collagen innovation for healthcare uses.

CEO Mr. Yehiel Tal · 39 employees · Israel · https://collplant.com